Compound profile
Cagrilintide
Stronger clinical signalAlso known as: long-acting amylin analogue · CagriSema component
A long-acting amylin-receptor analogue from Novo Nordisk, studied alone and paired with semaglutide (as "CagriSema") for weight management and type 2 diabetes. Currently one of the most-discussed "next after tirzepatide/retatrutide" names in metabolic-peptide circles.
Overview
Cagrilintide is a synthetic long acting analogue of amylin, a hormone the pancreas releases alongside insulin after meals to help regulate appetite, slow digestion, and signal fullness to the brain. Novo Nordisk engineered it starting from a pramlintide like amylin backbone rather than native human amylin, since pramlintide's sequence is less prone to the fibril formation that made native amylin difficult to develop as a drug in the first place.
The molecule is a 37 amino acid peptide carrying a C18 fatty diacid chain attached through a lysine side chain, the same acylation approach used in semaglutide and liraglutide. That fatty chain lets the peptide bind reversibly to albumin in the blood, which stretches its half life from the roughly 13 minutes of native amylin out to around 7 to 8 days and makes once weekly subcutaneous dosing possible.
Cagrilintide has not spent much time as a standalone drug candidate. Most of its clinical program runs through CagriSema, a combination product that pairs cagrilintide with semaglutide, the active ingredient in Ozempic and Wegovy, in a single once weekly injection. Novo Nordisk has filed for FDA approval of CagriSema for chronic weight management, and phase 3 data for the combination are now published, but cagrilintide by itself remains investigational and is not approved anywhere as a standalone medicine.
Human evidence for cagrilintide is concentrated in trials sponsored by Novo Nordisk, both monotherapy dose finding studies and the larger CagriSema program in obesity and type 2 diabetes. That is a narrower, more industry concentrated evidence base than an approved drug with years of post market surveillance, though the trial quality itself, randomized and placebo controlled, is high by peptide standards.
Mechanism (plain language)
Activates amylin receptors, which slow gastric emptying and reduce food intake through a mechanism distinct from (but complementary to) GLP-1 receptor agonism. Combining it with semaglutide is intended to hit appetite regulation from two hormone systems at once.
How it works
Amylin is normally co-secreted with insulin from pancreatic beta cells after eating, and it acts mainly in the brainstem and hypothalamus rather than on the gut directly. It slows gastric emptying so food moves into the small intestine more gradually, and it acts on appetite centers to promote a feeling of fullness and reduce food intake, working through a distinct receptor system from the incretin hormones GLP-1 and GIP.
Cagrilintide is designed to mimic and prolong that natural amylin signal. By activating amylin receptors continuously over a week instead of in short bursts after each meal, it is intended to produce a steadier reduction in appetite and food intake than the native hormone could achieve on its own. Because amylin and GLP-1 work through separate receptor systems that both converge on appetite and satiety circuits, researchers pair cagrilintide with semaglutide on the theory that hitting both pathways at once produces a larger combined effect on food intake and weight than either hormone system alone, which is the rationale behind CagriSema.
What research suggests
Randomized trials of cagrilintide alone and of the cagrilintide+semaglutide combination report substantial weight loss versus placebo and versus either component alone, with larger phase 3 data now published for adults with overweight or obesity.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Weight reduction as monotherapy
A phase 2 trial in adults with obesity reported roughly 11 percent body weight loss at 26 weeks with cagrilintide alone versus about 3 percent with placebo.
Larger weight loss in combination with semaglutide
Phase 3 CagriSema trials report body weight reductions in the low twenty percent range at roughly 68 weeks, greater than either cagrilintide or semaglutide produced individually in comparative trials.
Appetite and food intake reduction
Trial data and mechanistic studies describe reduced hunger and food intake attributed to combined amylin and GLP-1 receptor signaling on satiety circuits in the brain.
Glycemic effects in combination
Trials in people with type 2 diabetes report improved glycemic control when cagrilintide is combined with semaglutide, alongside the weight loss findings.
Uncertainties & risks
Investigational combination as of last review, not broadly approved for general consumer use. GI adverse events (nausea, vomiting, diarrhea) are common and were more frequent with the combination than placebo in trials. Long-term safety and lean-mass effects during rapid weight loss are still being characterized.
Cagrilintide is still investigational. It has not been approved by the FDA or any other major regulator as a standalone drug, and the more advanced regulatory pathway, the CagriSema combination, is still under review as of this writing. Anyone encountering cagrilintide outside a clinical trial is looking at an unapproved research compound, not a vetted medicine. Gastrointestinal side effects, nausea, vomiting, and diarrhea, are the most consistently reported issue across cagrilintide and CagriSema trials, similar to the pattern seen with GLP-1 drugs, and they tend to be more noticeable during dose escalation. Because amylin analogues are newer to large scale human trials than GLP-1 drugs, the long term safety picture, including effects on lean mass during rapid weight loss and any signal specific to sustained amylin receptor activation, is less mature than for older incretin therapies. Most published human data comes from Novo Nordisk sponsored trials, which is not unusual for an investigational drug but does mean independent, non sponsor replication is still limited.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.